Posted On: 12/17/2015 10:14:24 PM
Post# of 72446
Market cap comparison. "Which one isn't like the others?"
•CTIX 166M 3 drugs in 4 clinical trials
•SYN 221 M 2 drugs in 2 clinical trials (prevent c.difficile infections in people who are taking IV antibiotics, and an IBS drug)
•AVXL 235M (1 drug in stage 1 trial, 1 received grant for preliminary Parkinson's trial, animal studies on seizure disorders)
•ARWR 364M 2 drugs in 2 clinical trials -- hepatitis B, and a rare liver disease
•AXON 2.02 BILLION 0 drugs in clinical trials, one failed Alzheimers drug purchased from big pharma for 5 million, other drug in negotiations for purchase
Efficient market theory, huh?
And another question is: "Which stock is most underpriced per clinical trial in progress?"
Disclosure: I am currently long AVXL too, have owned SYN and will buy again if it gets down closer to 2. Wouldn't buy AXON if Cramer held a gun to my head.
•CTIX 166M 3 drugs in 4 clinical trials
•SYN 221 M 2 drugs in 2 clinical trials (prevent c.difficile infections in people who are taking IV antibiotics, and an IBS drug)
•AVXL 235M (1 drug in stage 1 trial, 1 received grant for preliminary Parkinson's trial, animal studies on seizure disorders)
•ARWR 364M 2 drugs in 2 clinical trials -- hepatitis B, and a rare liver disease
•AXON 2.02 BILLION 0 drugs in clinical trials, one failed Alzheimers drug purchased from big pharma for 5 million, other drug in negotiations for purchase
Efficient market theory, huh?
And another question is: "Which stock is most underpriced per clinical trial in progress?"
Disclosure: I am currently long AVXL too, have owned SYN and will buy again if it gets down closer to 2. Wouldn't buy AXON if Cramer held a gun to my head.
(0)
(0)
